ARCC‐4 showed good in vitro potency including low‐nanomolar DC50 (half‐maximal degradation concentrations) value, moderate inhibition on proliferation of prostate cancer cells with better antiproliferative effects on enzalutamide‐resistant AR mutant cells. Here, AR is linked to prostate cancer.